Foundayo: Lilly's New Oral GLP-1 Pill for Weight Loss Now in US
Foundayo (orforglipron), Eli Lilly's innovative once-daily oral GLP-1 pill, is now available in the United States for adults with obesity or overweight with weight-related medical problems. Approved by the US Food and Drug Administration (FDA) on April 1, 2026, this medication represents a convenient advancement in GLP-1 receptor agonist therapy, offering weight management without injections. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and maintain it long-term.
What is Foundayo and How Does It Work?
Foundayo is a once-daily pill designed for weight loss that can be taken without food or water restrictions, making it a user-friendly option compared to injectable GLP-1 therapies like semaglutide (Ozempic or Wegovy). As a GLP-1 receptor agonist, orforglipron mimics the glucagon-like peptide-1 hormone, which regulates appetite, slows gastric emptying, and promotes satiety. This mechanism addresses the root causes of obesity, such as hormonal imbalances that drive overeating and fat storage.
For patients tired of needles or complex dosing, Foundayo simplifies adherence. Clinical data from Lilly's rigorous ATTAIN program underscores its efficacy, positioning it as a potential game-changer in metabolic health for those qualifying under FDA criteria: adults with BMI ≥30 (obesity) or BMI ≥27 with conditions like hypertension or type 2 diabetes.
Availability: LillyDirect, Telehealth, and Retail Pharmacies
People can now access Foundayo via LillyDirect and telehealth providers, with shipments to retail pharmacies nationwide beginning April 9, 2026. "Foundayo delivers meaningful weight loss - an average of 27 pounds at the highest dose - and we made the path from prescription to doorstep as simple as possible," said Ilya Yuffa, Executive Vice President and President of Lilly USA and Global Customer Capabilities. "Millions of Americans can now connect with a health care professional to determine if Foundayo is right for them and receive the medicine at their door through LillyDirect's free home delivery, or access it through telehealth providers or local retail pharmacies."
This multi-channel rollout ensures broad accessibility, from direct-to-consumer home delivery to traditional pharmacy pickups, reducing barriers for patients in rural or underserved areas.
Proven Results from the ATTAIN Clinical Trials
ATTAIN-1 Trial Highlights
Supported by the ATTAIN clinical trial program, Foundayo demonstrated significant weight reduction. In the ATTAIN-1 trial, individuals taking the highest dose of Foundayo who stayed on treatment lost an average of 27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) with placebo. Even among participants taking Foundayo regardless of trial completion, the average loss was 25 pounds (11.1%), versus 5.3 pounds (2.1%) with placebo.
- Highest dose completers: 27.3 pounds (12.4%) vs. placebo
- All Foundayo participants: 25 pounds (11.1%) vs. placebo
Cardiovascular and Metabolic Benefits
Beyond weight loss, Foundayo led to reductions in key cardiovascular risk markers across all doses, including waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure. These improvements are crucial for patients with weight-related conditions, as excess adiposity often exacerbates heart disease, dyslipidemia, and hypertension.
In the broader context of GLP-1 therapies, these outcomes align with class-wide benefits observed in drugs like tirzepatide (Mounjaro/Zepbound), but Foundayo's oral format may improve patient satisfaction and persistence.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Pricing and Cost-Saving Options
Foundayo is available starting at $149 per month at the lowest dose for self-pay patients. Eligible commercially insured individuals with coverage for Foundayo may pay as little as $25 per month with the Foundayo savings card. Additionally, eligible Medicare Part D patients may access it for $50 per month beginning July 1, 2026.
| Dose/Patient Type | Monthly Cost |
|---|---|
| Lowest dose (self-pay) | $149 |
| Commercially insured (savings card) | As low as $25 |
| Medicare Part D (from July 2026) | $50 |
Patients should verify insurance coverage and explore LillyDirect for transparent pricing tools.
Safety Profile and Important Warnings
Common Side Effects
The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These gastrointestinal issues are typical for GLP-1 agonists and often diminish over time with consistent use.
Serious Risks
Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for symptoms such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath—if present, contact your healthcare provider immediately. Use with other GLP-1 receptor agonist medicines is not recommended. It is not known whether Foundayo is safe and effective for use in children.
For those on medications like insulin or sulfonylureas, dose adjustments may be needed to avoid hypoglycemia. Tools like Shotlee can help track symptoms and side effects, ensuring proactive management with your doctor.
Who Should Consider Foundayo? Patient Guidance
Ideal candidates are adults with obesity or overweight plus comorbidities who struggle with lifestyle changes alone. Consult a healthcare provider to assess suitability, especially if you have a history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or pancreatitis.
Compared to injectables, Foundayo offers convenience but similar efficacy profiles. Discuss titration schedules—starting low to minimize GI upset—and integration with diet/exercise for optimal results.
Key Takeaways: What This Means for Patients
- Foundayo provides up to 27 pounds of average weight loss in trials, with CV risk reductions.
- Available now via LillyDirect/telehealth; pharmacies from April 9, 2026.
- Affordable options: $25-$149/month depending on insurance.
- Monitor for thyroid symptoms; avoid combining with other GLP-1s.
- Pair with lifestyle changes for sustained success.
In summary, Foundayo expands oral GLP-1 options, making weight management more accessible. Speak with your doctor to see if it's right for your metabolic health journey.
